BE2024C508I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2024C508I2 BE2024C508I2 BE2024C508C BE2024C508C BE2024C508I2 BE 2024C508 I2 BE2024C508 I2 BE 2024C508I2 BE 2024C508 C BE2024C508 C BE 2024C508C BE 2024C508 C BE2024C508 C BE 2024C508C BE 2024C508 I2 BE2024C508 I2 BE 2024C508I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55049904P | 2004-03-05 | 2004-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2024C508I2 true BE2024C508I2 (cs) | 2024-08-08 |
Family
ID=34961010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2024C508C BE2024C508I2 (cs) | 2004-03-05 | 2024-03-04 |
Country Status (31)
| Country | Link |
|---|---|
| US (12) | US7858632B2 (cs) |
| EP (2) | EP2343282B1 (cs) |
| JP (4) | JP4717876B2 (cs) |
| KR (1) | KR100822530B1 (cs) |
| CN (1) | CN1930135B (cs) |
| AR (1) | AR047992A1 (cs) |
| AU (1) | AU2005229331B2 (cs) |
| BE (1) | BE2024C508I2 (cs) |
| BR (2) | BR122018003623B8 (cs) |
| CA (1) | CA2557372C (cs) |
| CY (2) | CY1113450T1 (cs) |
| DK (1) | DK1725540T5 (cs) |
| ES (2) | ES2391636T3 (cs) |
| FI (1) | FIC20240007I1 (cs) |
| FR (1) | FR24C1011I2 (cs) |
| HR (1) | HRP20120901T1 (cs) |
| HU (1) | HUS2400005I1 (cs) |
| IL (2) | IL177438A (cs) |
| LT (1) | LTC1725540I2 (cs) |
| LU (1) | LUC00333I2 (cs) |
| MY (1) | MY145465A (cs) |
| NL (1) | NL301261I2 (cs) |
| NO (4) | NO339497B1 (cs) |
| NZ (1) | NZ549069A (cs) |
| PL (1) | PL1725540T3 (cs) |
| PT (1) | PT1725540E (cs) |
| RU (1) | RU2422441C2 (cs) |
| SI (1) | SI1725540T1 (cs) |
| TW (1) | TWI313604B (cs) |
| WO (1) | WO2005095359A1 (cs) |
| ZA (1) | ZA200606880B (cs) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2343282B1 (en) * | 2004-03-05 | 2015-07-22 | F. Hoffmann-La Roche AG | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
| WO2006050265A2 (en) * | 2004-10-29 | 2006-05-11 | Musc Foundation For Research Development | Ceramides and apoptosis-signaling ligand |
| JP4850912B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン |
| WO2007025899A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| CA2620129C (en) * | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| AU2006286601B2 (en) * | 2005-09-01 | 2012-07-05 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
| ATE529413T1 (de) * | 2005-09-01 | 2011-11-15 | Hoffmann La Roche | Verfahren zur synthese von aryloxydiaminopyrimidinen |
| EP1770089A1 (en) * | 2005-10-03 | 2007-04-04 | Institut Pasteur | Pyranodibenzofuran derivatives with antifungal and antibacterial activity |
| CN102432548A (zh) * | 2006-10-04 | 2012-05-02 | 弗·哈夫曼-拉罗切有限公司 | 合成苯氧基二氨基嘧啶衍生物的方法 |
| ES2367455T3 (es) * | 2006-11-09 | 2011-11-03 | F. Hoffmann-La Roche Ag | Arilamidas sustituidas por tiazol u oxazol. |
| WO2008104472A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| CN101679246A (zh) | 2007-03-30 | 2010-03-24 | 盐野义制药株式会社 | 新型吡咯啉酮衍生物以及包含其的药物组合物 |
| KR20100098653A (ko) | 2007-11-21 | 2010-09-08 | 디코드 제네틱스 이에이치에프 | 염증의 치료를 위한 바이아릴 ｐｄｅ４ 억제제 |
| EP2336109A4 (en) * | 2008-09-25 | 2012-05-02 | Shionogi & Co | NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME |
| BRPI0921278A2 (pt) | 2008-11-06 | 2015-08-25 | Musc Found For Res Dev | Inibidores lisossomotrópicos de ceramidase ácida |
| CN102224140B (zh) | 2008-11-24 | 2014-04-16 | 巴斯夫欧洲公司 | 包含热潜性碱的可固化组合物 |
| AU2009332952A1 (en) * | 2008-12-30 | 2011-07-21 | Musc Foundation For Research Development | Sphingo-guanidines and their use as inhibitors of sphingosine kinase |
| CN102395571B (zh) | 2009-02-13 | 2015-12-16 | 盐野义制药株式会社 | 三嗪衍生物及含有该三嗪衍生物的药物组合物 |
| CN102753177A (zh) * | 2009-08-17 | 2012-10-24 | 纪念斯隆-凯特琳癌症中心 | 热休克蛋白结合化合物、组合物以及其制备和使用方法 |
| JP6075621B2 (ja) * | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| AU2011290261B2 (en) | 2010-08-10 | 2014-11-06 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity |
| US9550763B2 (en) | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| MY195728A (en) | 2013-08-23 | 2023-02-07 | Afferent Pharmaceuticals Inc | Diaminopyrimidine P2x3 and P2x 2/3 Receptor Modulators for Treatment of Acute, Sub-Acute or Chronic Cough |
| BR112016026470A8 (pt) | 2014-05-13 | 2021-07-20 | Memorial Sloan Kettering Cancer Center | composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto |
| EP3164132A4 (en) | 2014-07-03 | 2018-02-21 | Afferent Pharmaceuticals Inc. | Methods and compositions for treating diseases and conditions |
| PL3192512T3 (pl) | 2014-09-09 | 2020-03-31 | Astellas Pharma Inc. | Nowa kompozycja farmaceutyczna do zapobiegania i/albo leczenia nietrzymania moczu |
| RU2585727C1 (ru) * | 2014-12-12 | 2016-06-10 | Наталья Борисовна Гусева | Способ лечения детей с гиперактивным мочевым пузырем |
| PT3355889T (pt) | 2015-09-29 | 2023-04-26 | Afferent Pharmaceuticals Inc | Moduladores de recetores de diaminopirimidina p2x3 e p2x2/3 para utilização no tratamento da tosse |
| CA3016773A1 (en) * | 2016-03-14 | 2017-09-21 | Ronald Charles Hawley | Pyrimidines and variants thereof, and uses therefor |
| CA3018180C (en) | 2016-03-25 | 2024-02-20 | Ronald Charles Hawley | Pyrimidines and variants thereof, and uses therefor |
| CN106083653A (zh) * | 2016-06-06 | 2016-11-09 | 江苏天和制药有限公司 | 奥美普林中间体肉桂腈的合成方法 |
| US10676444B2 (en) * | 2016-12-20 | 2020-06-09 | Afferent Pharmaceuticals, Inc. | Crystalline salts and polymorphs of a P2X3 antagonist |
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
| MX2020011258A (es) | 2018-04-23 | 2021-01-20 | Merck Sharp & Dohme Llc | Proceso novedoso para sintesis de un compuesto de fenoxi diaminopirimidina. |
| EP3807243B1 (en) * | 2018-06-15 | 2024-05-22 | Pharmathen S.A. | A novel process for the preparation of tapentadol |
| AU2020265327B2 (en) * | 2019-04-30 | 2025-09-11 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| BR112021021721A2 (pt) * | 2019-04-30 | 2021-12-28 | Beijing Tide Pharmaceutical Co Ltd | Forma sólida de composto de diaminopirimidina ou hidrato do mesmo, método de preparação para a mesma e aplicação da mesma |
| WO2020239952A1 (en) * | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| EP3981765A4 (en) * | 2019-06-06 | 2023-05-31 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR USE |
| CN110551147B (zh) * | 2019-09-29 | 2021-11-26 | 蚌埠产品质量监督检验研究院 | 一种3-环丙基苯硼酸的合成方法 |
| TWI849314B (zh) * | 2020-06-01 | 2024-07-21 | 日商住友化學股份有限公司 | 化合物、樹脂、抗蝕劑組成物及抗蝕劑圖案的製造方法 |
| JP2023536986A (ja) | 2020-08-13 | 2023-08-30 | 上海拓界生物医薬科技有限公司 | ベンズイミダゾール誘導体、その調製方法及び医薬用途 |
| EP4214195A1 (en) | 2020-09-17 | 2023-07-26 | Teva Pharmaceuticals International GmbH | Solid state forms of gefapixant and process for preparation thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2658897A (en) | 1951-06-27 | 1953-11-10 | Burroughs Wellcome Co | 2, 4-diamino-5-benzyl pyrimidines |
| US2657206A (en) * | 1951-07-30 | 1953-10-27 | Burroughs Wellcome Co | 2, 4-diamino-5-aryloxy-pyrimidines |
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| US2909522A (en) | 1957-02-21 | 1959-10-20 | Burroughs Wellcome Co | Trialkoxybenzylpyrimidines and method |
| GB1261455A (en) * | 1969-03-06 | 1972-01-26 | Burroughs Wellcome Co | Improvements in or relating to substituted acrylonitriles |
| US3991050A (en) | 1969-03-06 | 1976-11-09 | Burroughs Wellcome Co. | Preparation of β-Amino-α-benzylacrylonitriles |
| US3852276A (en) | 1969-03-06 | 1974-12-03 | Burroughs Wellcome Co | 5-benzyl pyrimidines intermediate therefore, and method |
| US3849470A (en) | 1969-03-06 | 1974-11-19 | Burroughs Wellcome Co | 5-benzyl pyrimidines intermediates therefore,and method |
| US3855265A (en) | 1969-03-06 | 1974-12-17 | Burroughs Wellcome Co | 5-benzyl pyrimidines intermediates therefore, and method |
| US3850927A (en) | 1969-03-06 | 1974-11-26 | Burroughs Wellcome Co | 5-benzyl pyrimidines intermediates therefore,and method |
| US4052553A (en) | 1969-03-06 | 1977-10-04 | Burroughs Wellcome Co. | 5-benzyl pyrimidines intermediates therefore, and method |
| US3878252A (en) * | 1970-09-24 | 1975-04-15 | Burroughs Wellcome Co | Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide |
| BR6915082D0 (pt) * | 1969-05-16 | 1973-03-08 | Wellcome Found | Processo de preparacao de benzil-pirimidinas |
| CH513181A (de) | 1969-06-12 | 1971-09-30 | Hoffmann La Roche | Verfahren zur Herstellung von N-Oxyden von Benzylpyrimidinen |
| US4143227A (en) | 1973-02-26 | 1979-03-06 | Hoffmann-La Roche Inc. | Process for substituted 5-benzyl-2,4-diamino-pyrimidines |
| US4255574A (en) | 1973-02-26 | 1981-03-10 | Hoffmann-La Roche Inc. | Process for preparing 2,4-diamino-pyrimidines |
| US3931181A (en) | 1973-07-27 | 1976-01-06 | Hoffmann-La Roche Inc. | 2,4-Diamino-5-benzylpyrimidines |
| US4515948A (en) | 1973-09-12 | 1985-05-07 | Hoffmann-La Roche Inc. | 2,4-Diamino-5-(4-amino and 4-dimethylamino-3,5-dimethoxy benzyl)pyrimidines |
| CH591457A5 (cs) | 1973-11-08 | 1977-09-15 | Hoffmann La Roche | |
| US3940393A (en) | 1974-06-21 | 1976-02-24 | American Home Products Corporation | Synthesis of 2,6-diaminopyrimidines |
| US4039543A (en) | 1974-12-24 | 1977-08-02 | Hoffmann-La Roche Inc. | Benzylpyrimidines |
| US4033962A (en) | 1975-06-26 | 1977-07-05 | Hoffman-La Roche Inc. | 2,4-Diamino-pyrimidine derivatives and processes |
| GB1582245A (en) | 1976-06-09 | 1981-01-07 | Wellcome Found | Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives |
| US4115650A (en) | 1976-11-17 | 1978-09-19 | Hoffmann-La Roche Inc. | Process for preparing 2,4-diamino-5-(substituted benzyl)-pyrimidines |
| US4075209A (en) | 1977-02-07 | 1978-02-21 | Hoffmann-La Roche, Inc. | Process for preparing substituted 2,4-diaminopyrimidines and isoxazole intermediate |
| FR2397407A2 (fr) | 1977-07-11 | 1979-02-09 | Dick Pierre | Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides |
| US4258045A (en) | 1979-11-30 | 1981-03-24 | Merck & Co., Inc. | Inhibitor of dihydrofolate reductase |
| DE3045720A1 (de) | 1980-12-04 | 1982-07-08 | Basf Ag, 6700 Ludwigshafen | N-pyrimidinyl-carbaminsaeureester, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| FR2502152A1 (fr) | 1981-03-20 | 1982-09-24 | Panmedica Laboratoires | Nouveaux derives solubles n2 substitues de la diamino-2,4-benzyl-5-pyrimidines, leur procede de preparation et medicaments les contenant |
| IT1138146B (it) | 1981-08-11 | 1986-09-17 | Proter Spa | Processo per la produzione della 2,4-diammino-(3,5-dimetossi-4-metos sietossi-benzil)-pirimidina |
| GB2116962A (en) * | 1982-03-18 | 1983-10-05 | Ciba Geigy Ag | Nitriles; pyrimidines |
| US4590271A (en) | 1982-05-01 | 1986-05-20 | Burroughs Wellcome Co. | 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials |
| US4587341A (en) | 1982-05-07 | 1986-05-06 | Burroughs Wellcome Co. | 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials |
| US4515574A (en) * | 1983-02-16 | 1985-05-07 | The Zeller Corporation | Universal joint seal with multiple lips |
| DE3603577A1 (de) | 1986-02-06 | 1987-08-13 | Joachim K Prof Dr Seydel | Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit |
| FR2595697B1 (fr) | 1986-03-13 | 1988-07-08 | Rousselot Cie | Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant |
| HU199683B (en) | 1987-07-22 | 1990-03-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions analgesic, antiphlogistic, antipyretic, antianginic and/or antioxidative activity |
| US4996198A (en) | 1988-07-11 | 1991-02-26 | Hoffmann-La Roche Inc. | Anticoccidial composition |
| US5240640A (en) | 1990-06-04 | 1993-08-31 | Coulter Corporation | In situ use of gelatin or an aminodextran in the preparation of uniform ferrite particles |
| US5258373A (en) | 1991-07-17 | 1993-11-02 | Hoffmann-La Roche Inc. | Anticoccidial compositions |
| TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
| IL111959A (en) | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
| WO1996016963A1 (de) | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
| CA2162630C (en) * | 1994-11-25 | 2007-05-01 | Volker Breu | Sulfonamides |
| US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6136971A (en) | 1998-07-17 | 2000-10-24 | Roche Colorado Corporation | Preparation of sulfonamides |
| US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| US6211185B1 (en) | 1999-05-05 | 2001-04-03 | Veterinary Pharmacy Corporation | Concentrate comprising a sulfonamide in solution, a 2,4-diaminopyrimidine in stable suspension within said solution, and a suspending agent |
| US6596719B1 (en) | 1999-09-03 | 2003-07-22 | Actelio Pharmaceuticals Ltd. | 6 alkoxy-4-pyrimidinyl bis-sulfonamides |
| HU228449B1 (en) | 1999-09-24 | 2013-03-28 | Janssen Pharmaceutica Nv | Antiviral compositions |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| US6515198B2 (en) * | 2000-02-15 | 2003-02-04 | Syntex (U.S.A.) Llc | Use of purinergic receptor modulators and related reagents |
| WO2001081335A1 (en) | 2000-04-20 | 2001-11-01 | Actelion Pharmaceuticals Ltd | Pyrimidine-sulfonamides having endothelin-antagonist activity |
| AU2001265871A1 (en) | 2000-04-25 | 2001-11-07 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
| MY140724A (en) | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
| WO2002024665A1 (en) | 2000-09-25 | 2002-03-28 | Actelion Pharmaceuticals Ltd | Arylalkane-sulfonamides having endothelin-antagonist activity |
| EP1693372A1 (en) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Novel Sulfamides and their use as endothelin receptor antagonists |
| US6423720B1 (en) | 2001-02-01 | 2002-07-23 | Duquesne University Of The Holy Ghost | Pyrimidine compounds and methods for making and using the same |
| WO2002083650A1 (en) | 2001-04-11 | 2002-10-24 | Actelion Pharmaceuticals Ltd | Novel sulfonylamino-pyrimidines |
| CA2447671C (en) * | 2001-05-18 | 2013-01-08 | Abbott Laboratories | Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| EP2343282B1 (en) * | 2004-03-05 | 2015-07-22 | F. Hoffmann-La Roche AG | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
| AU2006286601B2 (en) * | 2005-09-01 | 2012-07-05 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
| JP4850912B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ３ｘ２／３モジュレーターとしてのジアミノピリミジン |
| CA2620129C (en) * | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2008104472A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
-
2005
- 2005-02-25 EP EP10179618.3A patent/EP2343282B1/en not_active Expired - Lifetime
- 2005-02-25 PT PT05715558T patent/PT1725540E/pt unknown
- 2005-02-25 CA CA2557372A patent/CA2557372C/en not_active Expired - Lifetime
- 2005-02-25 PL PL05715558T patent/PL1725540T3/pl unknown
- 2005-02-25 SI SI200531625T patent/SI1725540T1/sl unknown
- 2005-02-25 AU AU2005229331A patent/AU2005229331B2/en not_active Expired
- 2005-02-25 DK DK05715558.2T patent/DK1725540T5/da active
- 2005-02-25 EP EP05715558A patent/EP1725540B1/en not_active Expired - Lifetime
- 2005-02-25 ES ES05715558T patent/ES2391636T3/es not_active Expired - Lifetime
- 2005-02-25 KR KR1020067017924A patent/KR100822530B1/ko not_active Expired - Lifetime
- 2005-02-25 JP JP2007501184A patent/JP4717876B2/ja not_active Expired - Lifetime
- 2005-02-25 RU RU2006135203/04A patent/RU2422441C2/ru active
- 2005-02-25 HR HRP20120901TT patent/HRP20120901T1/hr unknown
- 2005-02-25 ES ES10179618.3T patent/ES2548022T3/es not_active Expired - Lifetime
- 2005-02-25 BR BR122018003623A patent/BR122018003623B8/pt active IP Right Grant
- 2005-02-25 CN CN2005800070982A patent/CN1930135B/zh not_active Expired - Lifetime
- 2005-02-25 BR BRPI0508461A patent/BRPI0508461B8/pt active IP Right Grant
- 2005-02-25 NZ NZ549069A patent/NZ549069A/en not_active IP Right Cessation
- 2005-02-25 WO PCT/EP2005/002020 patent/WO2005095359A1/en active Application Filing
- 2005-03-03 AR ARP050100813A patent/AR047992A1/es active IP Right Grant
- 2005-03-03 US US11/071,555 patent/US7858632B2/en active Active
- 2005-03-03 MY MYPI20050871A patent/MY145465A/en unknown
- 2005-03-04 TW TW094106612A patent/TWI313604B/zh not_active IP Right Cessation
-
2006
- 2006-08-10 IL IL177438A patent/IL177438A/en active IP Right Grant
- 2006-08-17 ZA ZA200606880A patent/ZA200606880B/en unknown
- 2006-09-08 NO NO20064065A patent/NO339497B1/no unknown
-
2010
- 2010-12-08 US US12/963,413 patent/US8846705B2/en not_active Expired - Lifetime
-
2011
- 2011-02-18 JP JP2011033729A patent/JP5576314B2/ja not_active Expired - Lifetime
- 2011-08-08 JP JP2011172873A patent/JP5465700B2/ja not_active Expired - Lifetime
-
2012
- 2012-01-10 IL IL217453A patent/IL217453A/en active IP Right Grant
- 2012-12-03 CY CY20121101179T patent/CY1113450T1/el unknown
-
2014
- 2014-06-03 JP JP2014115301A patent/JP5886898B2/ja not_active Expired - Lifetime
- 2014-08-06 US US14/453,409 patent/US9556127B2/en not_active Expired - Lifetime
-
2015
- 2015-04-27 NO NO20150504A patent/NO343755B1/no unknown
-
2016
- 2016-10-12 NO NO20161635A patent/NO20161635A1/no not_active Application Discontinuation
- 2016-12-19 US US15/383,135 patent/US20170096404A1/en not_active Abandoned
-
2017
- 2017-12-14 US US15/842,759 patent/US20180141919A1/en not_active Abandoned
-
2018
- 2018-08-09 US US16/100,193 patent/US20190016688A1/en not_active Abandoned
-
2019
- 2019-05-22 US US16/419,353 patent/US20190270713A1/en not_active Abandoned
- 2019-12-11 US US16/710,373 patent/US20200115347A1/en not_active Abandoned
-
2020
- 2020-09-25 US US17/032,486 patent/US20210009531A1/en not_active Abandoned
-
2022
- 2022-03-22 US US17/655,843 patent/US20230100975A1/en not_active Abandoned
-
2023
- 2023-04-27 US US18/308,282 patent/US20240158356A1/en not_active Abandoned
-
2024
- 2024-03-04 NL NL301261C patent/NL301261I2/nl unknown
- 2024-03-04 BE BE2024C508C patent/BE2024C508I2/nl unknown
- 2024-03-05 HU HUS2400005C patent/HUS2400005I1/hu unknown
- 2024-03-06 NO NO2024010C patent/NO2024010I1/no unknown
- 2024-03-12 FR FR24C1011C patent/FR24C1011I2/fr active Active
- 2024-03-12 LT LTPA2024508C patent/LTC1725540I2/lt unknown
- 2024-03-13 CY CY2024006C patent/CY2024006I1/el unknown
- 2024-03-13 FI FIC20240007C patent/FIC20240007I1/fi unknown
- 2024-03-14 LU LU00333C patent/LUC00333I2/fr unknown
- 2024-09-19 US US18/890,411 patent/US20250066309A1/en active Pending